Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
- A. Wolff, M. Hammond, +17 authors D. Hayes
- Medicine
- Archives of pathology & laboratory medicine
- 1 February 2014
PURPOSE
To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in… Expand
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
- M. Hammond, D. Hayes, +29 authors A. Wolff
- Medicine
- Journal of clinical oncology : official journal…
- 1 June 2010
PURPOSE
To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors… Expand
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
- M. Dowsett, T. Nielsen, +18 authors D. Hayes
- Medicine
- Journal of the National Cancer Institute
- 16 November 2011
Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the most widely used… Expand
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
- M. Hammond, D. Hayes, +29 authors A. Wolff
- Medicine
- Archives of pathology & laboratory medicine
- 1 June 2010
PURPOSE
To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors… Expand
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT)…
- I. Smith, M. Dowsett, +7 authors G. Walsh
- Medicine
- Journal of clinical oncology : official journal…
- 1 August 2005
PURPOSE
The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant… Expand
Aromatase inhibitors in breast cancer.
- I. Smith, M. Dowsett
- Medicine
- The New England journal of medicine
- 12 June 2003
Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine treatment of breast cancer. However, new aromatase inhibitors that are many times more potent and specific than… Expand
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health…
- J. Cuzick, M. Dowsett, +10 authors J. Forbes
- Medicine
- Journal of clinical oncology : official journal…
- 10 November 2011
PURPOSE
We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant recurrence beyond that obtained from… Expand
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
- A. Wolff, M. Hammond, +17 authors D. Hayes
- Medicine
- Journal of clinical oncology : official journal…
- 1 November 2013
PURPOSE
To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in… Expand
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
- G. Attard, A. Reid, +16 authors J. D. de Bono
- Medicine
- Journal of clinical oncology : official journal…
- 10 August 2009
PURPOSE
It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of… Expand
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
- M. Dowsett, I. Sestak, +7 authors J. Cuzick
- Medicine
- Journal of clinical oncology : official journal…
- 1 July 2013
PURPOSE
Risk of distant recurrence (DR) among women with estrogen receptor (ER) -positive early breast cancer is the major determinant of recommendations for or against chemotherapy. It is frequently… Expand